Key Insights

Highlights

Success Rate

95% trial completion (above average)

Published Results

25 trials with published results (44%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

3.5%

2 terminated out of 57 trials

Success Rate

95.3%

+8.8% vs benchmark

Late-Stage Pipeline

7%

4 trials in Phase 3/4

Results Transparency

61%

25 of 41 completed with results

Key Signals

25 with results95% success

Data Visualizations

Phase Distribution

46Total
Not Applicable (42)
P 3 (1)
P 4 (3)

Trial Status

Completed41
Recruiting4
Unknown3
Suspended2
Active Not Recruiting2
Withdrawn2

Trial Success Rate

95.3%

Benchmark: 86.5%

Based on 41 completed trials

Clinical Trials (57)

Showing 20 of 20 trials
NCT06285695Not ApplicableCompletedPrimary

Clareon Toric Study (T2-T9)

NCT07484191Not ApplicableRecruitingPrimary

Contralateral Claims Study of Clareon Vivity Pro

NCT07587138Not ApplicableNot Yet RecruitingPrimary

Clinical Evaluation of a Novel Trifocal IOL

NCT07502456Not ApplicableRecruitingPrimary

Clareon TruPlus Study

NCT06401551Not ApplicableCompletedPrimary

Clareon PanOptix Pro vs. Clareon PanOptix - Study B

NCT07147192Not ApplicableRecruitingPrimary

Feasibility Study of an Accommodating IOL Design

NCT07161635Not ApplicableActive Not RecruitingPrimary

Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs

NCT06166901Not ApplicableCompletedPrimary

Evaluation of Long-term Safety and Performance of PanOptix Trifocal Intraocular Lens (IOL)

NCT05852470Not ApplicableCompletedPrimary

Evaluation of Clareon Vivity/Vivity Toric

NCT06258707Not ApplicableRecruitingPrimary

Bicentric Clinical Investigation to Assess Safety and Performance of LuxBoost IOL

NCT06400745Not ApplicableCompletedPrimary

Clareon PanOptix Pro vs. Clareon PanOptix - Study A

NCT06541795Not ApplicableWithdrawnPrimary

Evaluation of AcrySof IQ Vivity Extended Vision Intraocular Lenses

NCT05796453Not ApplicableActive Not RecruitingPrimary

Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix

NCT05799950CompletedPrimary

A Real-World Evidence (RWE) Long-Term Follow-Up Study to Assess Outcomes of Alcon Monofocal Intraocular Lenses

NCT05202808Not ApplicableCompletedPrimary

RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study

NCT04529616CompletedPrimary

Single Center Exploratory Study To Evaluate The Use Of The RxSight Light Adjustable Lens (LAL) And The Light Delivery Device (LDD) To Improve Visual Outcomes

NCT04177771TerminatedPrimary

A Clinical Study to Evaluate The Safety and Effectiveness of The RxSight Light Adjustable Lens (LAL) In Subjects Desiring an Extended Depth of Focus

NCT05481125Not ApplicableCompleted

Clareon Toric vs Eyhance Toric

NCT01547442Not ApplicableSuspendedPrimary

Artisan Aphakia Lens for the Correction of Aphakia in Children

NCT01547429Not ApplicableSuspendedPrimary

Artisan Aphakia Lens for the Correction of Aphakia (Secondary) in Adults

Scroll to load more

Research Network

Activity Timeline